ASBrS Endorses Cryoablation for Low-Risk Breast Cancer, Boosting IceCure Medical

The American Society of Breast Surgeons has officially updated its 2026 Resource Guide to recommend cryoablation as a viable treatment option for carefully selected patients with biologically low-risk early-stage breast cancer. This clinical endorsement represents a significant milestone for IceCure Medical, whose ProSense® cryoablation system received FDA clearance in October 2025 for treating low-risk breast cancer in patients aged 70 and above. The guidance is expected to accelerate commercial adoption of the minimally invasive procedure across U.S. healthcare institutions.

Clinical Validation and Regulatory Momentum

The ASBrS update validates cryoablation technology as a legitimate treatment modality within the breast surgery toolkit, particularly for a specific patient demographic where traditional surgical approaches may carry elevated risks. IceCure Medical's ProSense® system now has dual endorsements: regulatory approval from the FDA and clinical guidance from one of the nation's most influential surgical societies.

Key milestones in this trajectory include:

• October 2025: FDA clearance for ProSense® cryoablation in low-risk breast cancer patients aged 70+
• 2026: ASBrS Resource Guide updated to include cryoablation recommendation
• Target patient population: Biologically low-risk, early-stage breast cancer cases requiring selective treatment approaches

The FDA clearance specifically addressed a demographic concern—elderly patients with comorbidities who may not tolerate surgery well. Cryoablation offers a less invasive alternative by using extreme cold to destroy cancer tissue, typically requiring only local anesthesia and minimal incisions. This therapeutic approach aligns with broader healthcare trends favoring less traumatic interventions for vulnerable populations.

Market Context: The Minimally Invasive Surgery Expansion

The breast cancer treatment landscape has undergone substantial evolution over the past decade. While traditional lumpectomy and mastectomy remain standard approaches, healthcare systems increasingly prioritize patient outcomes, reduced recovery times, and quality-of-life considerations. The global breast cancer treatment market exceeds $20 billion annually, with minimally invasive technologies representing one of the fastest-growing segments.

Cryoablation and similar thermal ablation technologies occupy a growing niche within interventional oncology. Competitors in this space include radiofrequency ablation (RFA) systems and other image-guided ablative techniques. However, cryoablation has demonstrated particular promise in breast applications due to better tissue visualization (the "iceball" is visible on imaging) and favorable safety profiles in early clinical data.

The ASBrS endorsement is particularly influential because:

• ASBrS represents approximately 4,000 breast surgeons across North America
• Guidelines from major surgical societies directly influence institutional protocols and insurance coverage decisions
• Resource guides establish standards of care that hospitals incorporate into surgical pathways
• The recommendation creates a clinical pathway for referring physicians to consider cryoablation earlier in treatment planning

This represents a shift toward precision oncology, where treatment selection becomes increasingly tailored to individual patient biology and risk profiles rather than applying one-size-fits-all protocols.

Investor Implications and Commercial Trajectory

For IceCure Medical shareholders, the ASBrS recommendation represents meaningful commercial validation beyond regulatory approval. While FDA clearance opens the door, clinical society endorsements often prove equally crucial for adoption rates and reimbursement decisions.

Several factors could drive adoption acceleration:

• Reimbursement expansion: Insurance companies often follow major society guidelines when establishing coverage policies. ASBrS recommendation strengthens IceCure's reimbursement negotiating position with major payers like UnitedHealth, Cigna, and Anthem.
• Hospital formulary adoption: Many institutions require procedural validation from established surgical societies before integrating new technologies into surgical suites.
• Physician confidence: Surgeons are more likely to adopt and offer procedures explicitly recommended by their professional societies.
• Training and credential expansion: ASBrS endorsement can facilitate training program development and surgeon credentialing for cryoablation.

The target population—patients aged 70+ with low-risk breast cancer—represents a substantial addressable market in aging developed economies. The U.S. has approximately 230,000 new breast cancer diagnoses annually, with roughly 25-30% occurring in patients aged 65 and older. Among elderly patients, risk stratification increasingly identifies subsets with "low-risk" biologic profiles amenable to less aggressive intervention.

However, commercialization faces typical adoption curve challenges. Physician training requirements, competition from established surgical techniques, and the need to build economic models demonstrating cost-effectiveness and improved outcomes remain critical hurdles. The company must demonstrate not just safety and efficacy but also that cryoablation delivers superior outcomes or cost benefits compared to conventional approaches.

Looking Forward: Clinical Evidence and Market Penetration

The success of IceCure Medical's commercial trajectory now depends on several forward-looking factors. Continued clinical evidence generation—particularly long-term recurrence-free survival data comparable to traditional surgery—will be essential for broader adoption beyond the initial elderly demographic.

Rapid market penetration may depend on:

• Prospective clinical trials demonstrating non-inferiority or superiority versus standard care
• Health economics studies showing cost-effectiveness when accounting for reduced operative time, anesthesia costs, and recovery expenses
• Real-world evidence from early adopting institutions documenting safety and efficacy in routine clinical practice
• Insurance coverage expansion to broader patient populations as clinical evidence accumulates
• Competitive positioning as other companies develop competing ablative technologies

The regulatory and clinical validation framework now in place positions IceCure Medical to execute a scaled commercialization strategy. The ASBrS endorsement removes a critical barrier to adoption—the skepticism from established surgical leaders. Rather, it provides explicit professional legitimacy for a treatment paradigm that challenges conventional surgical thinking.

As the breast cancer treatment field continues fragmenting into increasingly specialized, risk-stratified approaches, technologies like cryoablation that offer less invasive alternatives for appropriate patient populations are likely to capture meaningful market share. The 2026 ASBrS Resource Guide update represents a crucial step in that transition, translating regulatory approval into clinical momentum.